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Abstract
Beams of 4He and 16O nuclei are considered for ion-beam cancer therapy as alternative options
to protons and 12C nuclei. Spread-out Bragg peak (SOBP) distributions of physical dose and
relative biological effectiveness for 10% survival are calculated by means of our Geant4-based
Monte Carlo model for Heavy Ion Therapy (MCHIT) and the modified microdosimetric kinetic
model. The depth distributions of cell survival fractions are calculated for 1H, 4He, 12C and 16O
for tissues with normal (HSG cells), low and high radiosensitivity. In each case the cell survival
fractions were compared separately for the target volume, behind and in front of it. In the case
of normal radiosensitivity 4He and 12C better spare tissues in the entrance channel compared to
protons and 16O. The cell survival fractions calculated, respectively, for the entrance channel and
target volume are similar for 4He and 12C. When it is important to spare healthy tissues located
after the distal edge of the SOBP plateau, 4He can be recommended due to reduced nuclear
fragmentation of these projectiles. No definite advantages of 16O with respect to 12C were found,
with the except of an enhanced impact of these heavier projectiles on radioresistant tumors.
1 Introduction
The advantage of charged particles, in particular, protons and carbon nuclei, used for radiation therapy
of cancer consists in elevated dose delivered at the end of projectile range in tissues. The plateau of
the depth-dose distribution at the entrance of a monoenergetic beam terminates with a sharp Bragg
peak which can be targeted at the tumor. Such a dose profile helps to spare healthy tissues located
in front of the tumor as well as beyond the projectile range. Since a set of beam energies is typically
used in treatments to cover the whole tumor volume, the resulting dose distribution is characterized
by a spread-out Bragg peak (SOBP) [1, 2, 3] with a wide domain of elevated dose.
The damage of healthy tissues during therapy can be essentially reduced if the ratio between the
relative biological effectiveness (RBE) values at the SOBP region and plateau is favorable. As recog-
nized almost 40 years ago in radiobiological experiments with SOBP beams of light nuclei performed
at Berkeley [4], this RBE ratio is greater than 1 and increases with ion charge up to carbon. It was also
found that this ratio decreases for Ne and becomes less than 1. In 1994 first patient treatments with
beams of carbon nuclei started in Japan at National Institute of Radiological Sciences (NIRS) [5] and
in 1997 in Germany at Gesellschaft fu¨r Schwerionenforschung (GSI) [3]. Later the advantages of 12C
with respect to 3He and 20Ne were confirmed in experiments at NIRS with these nuclear beams [6]. As
explained [7], the RBE of 135MeV/u 12C beam with the linear energy transfer (LET) of 65 keV/µm
was found similar to the RBE of neutrons which have been used for treatment at NIRS during last
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20 years. This similarity also motivated the choice of carbon nuclei for treatments at NIRS. In the
last decades localized tumors have been successfully treated with beams of carbon nuclei at several
facilities constructed in Japan and Germany [8, 9, 10, 11, 12, 13].
Despite of the broad clinical experience collected worldwide with proton and carbon-ion beams,
other light nuclei can be also considered as future therapy options. The radiobiological properties of
proton and 12C beams were compared in several studies, see e.g. [14, 15]. However, less attention has
been paid so far to 4He or 16O and to their comparison with protons and 12C. There exist several
clinical rationale behind the use of 4He and 16O for therapy:
i) 4He and 16O beams have a reduced lateral spread of the dose distribution compared to protons;
ii) their RBE in the target volume is higher compared to protons;
iii) lower dose in the tail region and lower RBE in the plateau is expected for 4He compared to 12C
due to reduced nuclear fragmentation of 4He;
iv) 16O is a promising option for hypoxic tumors as it provides a higher dose averaged LET in the
target volume compared to 12C.
The choice of ion species and their energies at each new particle therapy facility [16, 17, 18]
essentially depends on LET and RBE of the projectiles under consideration. The distributions of
dose, LET and dose averaged LET of 1H, 4He, 6,7Li, 8Be, 10B, 12C, 14N and 16O nuclei of therapeutic
energies were studied [19, 20] by means of Monte Carlo simulations with SHIELD-HIT and FLUKA
codes, respectively. Similar distributions for 1H, 3He, 12C, 20Ne and 58Ni were calculated [21] with the
Geant4 toolkit to study their dependence on the ions mass, charge and energy. It was assumed [19]
that ions with LET above 20 keV/µm should be used for efficient cancer therapy as such species induce
on average two and more double strand breaks in DNA close to each other. However, as pointed out
in the same work, this limit is not sharp and ought to vary with ion mass and charge. This indicates
that the RBE of respective ions has to be additionally considered for an accurate comparison of their
biological action. Indeed, as shown in our recent work [22], there is no direct correspondence between
RBE and the frequency-mean linear energy y¯f , which represents LET, for monoenergetic beams of
therapeutic energies. Similar RBE values were estimated [22] at the peak and plateau regions which
are characterized, however, by very different y¯f .
As demonstrated [22], microdosimetry spectra for monoenergetic 1H, 4He, 7Li and 12C nuclei
propagating in a water phantom can be accurately described with our Monte Carlo model for Heavy-
Ion Therapy (MCHIT) [23], and this model coupled with the Microdosimetric Kinetic (MK) model [24,
25] can be used to calculate the respective RBE profiles. In the present work we evaluate 4He and
16O for cancer therapy as complementary options to 1H and 12C by considering the biological dose
distribution with a 6 cm SOBP delivered by these four projectiles. This is an important prerequisite for
planning radiobiological experiments with 4He and 16O SOBP beams and extending existing treatment
planning systems to operation with 4He and 16O.
The experimental data [7] collected at HIMAC for the 6 cm SOBP obtained by the moderation
of a 290MeV/u 12C beam are used as a reference. The results of microdosimetry simulations are
validated by comparison with microdosimetry data collected for 1H, 4He and 12C beams [25]. This
makes possible to predict the RBE and cell survival profiles for 16O beams and compare all four ion
species in a common framework.
2 Materials and methods
2.1 Monte Carlo modeling of propagation of ions in water
With the Monte Carlo model for Heavy Ion Therapy (MCHIT) [26, 23] the propagation of accelerated
protons and light nuclei of therapeutic energies in tissue-like media can be simulated. The model
is based on the Geant4 toolkit [27, 28] and takes into account all major physics processes relevant
to the interactions of beam particles with these materials. The Geant4 version 9.5 with patch 02 is
used to build the present version of MCHIT, which also simulates the interactions of various particles
with walled and wall-less Tissue Equivalent Proportional Counters (TEPC) thus providing respective
microdosimetry distributions.
The ionization of atoms and multiple Coulomb scattering on nuclei of the media are the most
important electromagnetic processes to simulate the energy loss and straggling of primary and sec-
ondary charged particles. Two predefined physics lists for electromagnetic processes are employed
in MCHIT, namely, G4EmStd (which uses the “Standard Electromagnetic Physics Option 3”) and
2
G4EmPen (which uses the Penelope models for low-energy processes). The low-energy thresholds for
production of δ-electrons are 990 eV for G4EmStd and 100 eV for G4EmPen. However, in order
to reduce the CPU time, cuts in range and energy thresholds for particle production are set differ-
ently for water, plastic of the TEPC wall and the TEPC sensitive volume filled with tissue-equivalent
gas [29]. A customized physics list, G4EmPen+IonGas, which is based on G4EmPen and the models
describing the ionization of gas media by ions, can be also used in calculations. As demonstrated [22],
G4EmStd and G4EmPen provide statistically equivalent results for microdosimetry spectra, which
agree well with the distributions measured for 4He [30], excluding the domains of low linear energy,
y <1 keV/µm, and around the maximum at y ∼15 keV/µm. However, the agreement between the
data and calculations is improved when G4EmPen+IonGas is used. Therefore, G4EmPen+IonGas is
involved in MCHIT also in the present work to simulate electromagnetic processes inside the TEPC
volume.
A therapeutic nuclear beam is attenuated in tissues due to the loss of beam nuclei in nuclear
fragmentation reactions, which generate secondary projectile and target fragments [23]. Nuclear re-
actions are taken into account in MCHIT to reproduce this effect. As shown [23], the build-up of
secondary fragments produced by 200MeV/u and 400MeV/u 12C beams is generally well described
with a customized physics list based on the Light Ion Binary Cascade model (G4BIC) [31] coupled
with the Fermi break-up model (G4FermiBreakUp) [32] responsible for subsequent decays of excited
nuclear fragments created at the first fast stage of nucleus-nucleus collisions. In the present work
G4BIC is used for proton, helium and lithium beams, while the Quantum Molecular Dynamics model
(G4QMD) [33] is involved in simulations with carbon and oxygen beams. More details on the physics
processes and respective Geant4 models involved in modeling with MCHIT are given in our recent
publications [23, 29, 22].
2.2 Microdosimetry simulations and calculations of RBE for monoener-
getic beams
The design and materials of specific TEPC models were thoroughly introduced in MCHIT. This made
possible to simulate the microdosimetry spectra measured with a walled TEPC at several positions
inside a water phantom irradiated by 185MeV/u 7Li and 300MeV/u 12C beams [34] and study the
impact of nuclear fragmentation reactions on these spectra [29, 22]. The influence of the positioning
of the TEPC with respect to the beam axis and the distortion of the spectra due to the pile-up of
individual events were investigated. After correcting for such effects the calculated microdosimetry
spectra agree well with the experimental data in general.
Following the validation of MCHIT for microdosimetry of monoenergetic 7Li and 12C beams [29,
22], this model is applied to microdosimetry of SOBP dose distributions considered in the present
work. In the measurements performed at HIMAC with a 6 cm SOBP for 160MeV 1H, 150MeV/u
4He and 290MeV/u 12C [25] the data for frequency-mean lineal energy, y¯f , dose-mean lineal energy,
y¯d, and saturation-corrected dose-mean lineal energy, y
∗ [35] were collected. The microdosimetry
spectra were measured with a walled TEPC corresponding to a tissue-equivalent sphere of 1 µm in
diameter.
According to the linear-quadratic (LQ) model the fraction of cells S survived after the impact of
the radiation dose D is calculated as
S = exp
[
−αD − βD2
]
. (1)
Following the modified MK model [25] applied to human salivary gland (HSG) tumor cells the pa-
rameter α is estimated as
α = α0 +
β
ρpir2d
y∗ , (2)
with the constant term α0 = 0.13 Gy
−1 representing the initial slope of the survival fraction curve in
the limit of zero LET and β = 0.05 Gy−2, ρ =1 g/cm3 as the density of tissue and rd =0.42 µm as the
radius of a sub-cellular domain in the MK model. The dependence of the α-parameter of the linear-
quadratic model on y∗ rather than on y¯d reflects the reduction of the RBE known as the saturation
effect. It means that an excessive local energy deposition does not boost biological effects induced by
high-LET particles [35]. As demonstrated [25], the same value of parameter β = 0.05 Gy−2 can be
used to fit the data on S with Eq. (1) for X-rays and ions. This justifies the assumption of the MK
model that β is independent of LET.
According to the LQ model the RBE10 for 10% survival of HSG cells is calculated using the
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following relation [36]:
RBE10 =
D10,R
D10
=
2βD10,R√
α2 − 4β ln (0.1)− α
, (3)
where D10 is the 10% survival dose of ions and D10,R = 5.0 Gy is the 10% survival dose of the
reference radiation (200 kVp X-rays) for HSG cells [36]. Finally, the biological dose Dbio is calculated
from RBE10 and physical dose:
Dbio = RBE10 D. (4)
2.3 Composing SOBP profiles from a library of pristine Bragg peaks
The computing time required for treatment planing in carbon-ion therapy can be reduced by using
pre-computed libraries of dose and RBE distributions for monoenergetic beams [37, 38, 39]. The aim
of the treatment planning is to find an optimum superposition of many beams with their individual
energy, position and intensity in order to obtain the prescribed biological SOBP dose profile. It is
expected that a similar approach will be also suitable for other therapeutic beams, like 4He and
16O. Therefore, we implemented a common algorithm to calculate the relative weights of pre-defined
monoenergetic beams of 1H, 4He, 12C and 16O to obtain flat biological SOBP distributions for each
projectile as a product of the physical dose and RBE calculated for mixed radiation field.
A library of depth-dose profiles and the corresponding microdosimetry spectra for different beam
energies and nuclei were calculated by Monte Carlo simulations with MCHIT. They are used as input
data for a procedure similar to one implemented at NIRS [7]. According to this procedure based on
the theory of dual radiation action [40] the survival fraction of cells exposed to mixed radiation is
calculated as:
Smix(D) = exp
(
−αmixD − βmixD
2
)
; (5)
αmix =
∑
fiαi; (6)
√
βmix =
∑
fi
√
βi. (7)
Here fi is the weight coefficient (fraction) of the local physical dose of the ith monoenergetic beam
which contribute to the total physical dose D, while αi and βi are the parameters of the LQ model
specific to ith monoenergetic beam. The parameters αi and βi are calculated along the beam axis
using MCHIT coupled with the modified MK model as described in Sec. 2.2. The resulting RBE10,mix
for the mixed radiation is calculated from the survival fraction of cells Smix(D) and it also depends
on the depth. RBE10 and RBE10,mix for the monoenergetic and SOBP (mixed) beams, respectively,
are considered in the following. They account for the relative biological effectiveness corresponding
to 10% survival of cells.
A dedicated algorithm to obtain fi for a given biological SOBP was developed. It starts with the
determination of the weight at the distal edge of the SOBP distribution and then calculates weights
for less energetic beams by adjusting their contribution to provide a flat SOBP plateau.
3 Results and discussion
3.1 Pristine Bragg peaks
Simulation results for monoenergetic 152.7MeV 1H, 152.1MeV/u 4He, 290MeV/u 12C and 345.4MeV/u
16O beams are shown in Figure 1. The beam energies were chosen to place the Bragg peaks of all four
beams at the depth of ∼161.8mm.
As expected, the 12C and 16O beams deposit much higher energy at the Bragg peak compared to
1H and 4He. However, higher energy deposition by 12C and 16O is also observed at the entrance and
tail region. Therefore, no clear advantages of therapeutic 12C and 16O beams with respect to 1H and
4He beams regarding healthy tissues can be inferred exclusively from the analysis of the considered
depth-dose distributions.
The RBE10 profiles for the considered
1H, 4He, 12C and 16O beams are shown in the middle panel
of Figure 1 and they differ from each other. The RBE10 for
12C beam estimated from the parameters of
a LQ fitting on survival curves of HSG cells with β fixed to 0.05 Gy−2 [25] is presented for comparison.
The RBE10 profile for
12C beam calculated with MCHIT coupled with the MK model agrees well with
the profile which is also calculated with MK, but using the measured microdosimetry data on y∗ [25].
A prominent difference between RBE10 profiles for
12C and 16O and the profile for 4He is seen in the
insert of Figure 1. The backward shift of the maximum of RBE10 of
12C and 16O with respect to
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Figure 1: Calculated energy deposition per beam particle (top panel), RBE10 for HSG cells (middle
panel) and biological dose (bottom panel) for 1H, 4He, 12C and 16O beams in water. The RBE10
calculated from measured values of y∗ [25] are shown by circles. The RBE10 estimated from LQ fitting
on survival curves of HSG cells [25] are presented by triangles. The biological dose distributions for
all ions were rescaled to get the same value at the maximum.
the position of the 4He maximum is due to the saturation effect. It is also found that 12C and 16O
nuclei are characterized by higher RBE values for 10% survival of HSG cells along the whole irradiated
medium. Their maximum values reach 2.9 and 3.1, respectively, close to the Bragg peak. At the same
time the RBE10 values for helium are relatively low at the entrance and tail regions and demonstrate
a steep rise to 2.2 at the Bragg peak position. Before the Bragg peak the RBE10 values for proton
beam are slightly below 1. and increase to 1.5 well after the distal edge of the proton Bragg peak.
This rise of RBE10 for proton beam is explained by the presence of secondary nucleons produced by
beam protons in water and propagating beyond the Bragg peak.
Finally, the biological dose profiles for 1H, 4He, 12C and 16O (a.u.) are presented in the bottom
panel of Figure 1. They were rescaled to get the same value at the maximum. The profiles for 4He,
12C and 16O are very similar to each other. They are characterized by a more sharp rise and fall of the
biological dose in the Bragg peak region compared to protons. After renormalization lower biological
dose for 4He, 12C and 16O is predicted at the entrance with respect to protons. SOBP profiles of
biological dose for all these projectiles are considered below.
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3.2 RBE distributions for 1H, 4He, 12C and 16O
As explained in Sec. 2.3, a given biological SOBP dose distribution is composed from a set of depth-
dose and depth-y∗ profiles calculated with MCHIT for monoenergetic beams. Such a library created
in the present work contains pristine Bragg curves with a 1 mm increment of the Bragg peak positions
which are within 90–175mm depth in water. Seven pristine Bragg peaks for 12C covering a 60 mm
domain in depth are shown in Figure 2 to illustrate the content of this library. The microdosimetry
variables which are also stored in the library as functions of depth are used to estimate RBE10 profiles
according to the MK model, see Sec. 2.3. The respective RBE10 distributions are shown in Figure 2
for the same beams. As seen in Figure 2, the height of the Bragg peak noticeably diminishes with
depth, while the maximum RBE10 remains almost constant (∼ 3) over the considered depth range.
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Figure 2: Energy deposition profiles for 12C in water in 10 mm steps (top panel) and the corresponding
RBE10 profiles for HSG cells calculated with MCHIT and the MK model (bottom panel).
A 6 cm-wide SOBP profile of biological dose for 290MeV/u 12C beam, which was built according
to the above-described procedure is shown in the top panel of Figure 3. Here and in the following
such profiles are normalized to 1 at the plateau in order to facilitate the comparison of various ion
species. The resulting distribution has a flat SOBP plateau with negligible fluctuations due to the
presence of individual Bragg peaks. In contrast, the corresponding SOBP distribution of the physical
dose, which is also shown in Figure 3 is not flat, but rather decreases with depth. The respective
RBE10 amounts to ∼ 1.6 at the proximal edge of the SOBP, while it is slightly above 2.5 at the distal
edge, see the bottom panel of Figure 3. The insert in the bottom panel of Figure 3 demonstrates the
calculated relative weights for monoenergetic beams used to build the SOBP distribution of biological
dose shown in Figure 3.
The 6 cm-wide RBE10,mix profiles calculated for HSG cells for 152.7MeV
1H, 152.1MeV/u 4He,
290MeV/u 12C and 345.4MeV/u 16O beams are presented in Figure 4. They were calculated within
the MK model basing on microdosimetry data generated by Monte Carlo simulations with MCHIT.
The reliability of these profiles can be proved by comparing them with RBE10,mix calculated by two
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Figure 3: A 6 cm-wide SOBP biological dose distribution in water for 290 MeV/u 12C ion beam and
the respective physical dose (top panel). RBE10,mix profile for HSG cells (bottom panel) and the
distribution of beam energy used to build the SOBP profiles (insert).
different approaches. In the first case, RBE10,mix is also calculated within the MK model, but on
the basis of measured y∗ values [25]. In the second approach, RBE10,mix is calculated using the
parameters of LQ fitting of survival curves of HSG cells with β fixed to 0.05 Gy−2 [25]. The profiles
based on MCHIT simulations agree very well with the RBE10,mix estimated on the basis of the two
set of experimental data, see Figure 4. In order to make such comparison, experimental values [25]
corresponding to 1H and 4He were shifted in depth due to the difference of beam energies used in
measurements and simulations.
A good agreement with data for 1H, 4He and 12C suggests that this method can be also applied to
16O beam. The distribution of RBE10,mix for
16O obtained on the basis of microdosimetry simulations
with MCHIT is shown in Figure 4 for comparison. The shapes of RBE10,mix profiles for
4He, 12C
and 16O are found to be similar with a rise of RBE for 12C and 16O at the proximal edge of the
SOBP distribution. A characteristic rise of RBE for 1H beyond 165 mm depth at the distal region
of the SOBP is found, similarly to the case of monoenergetic proton beam, Sec. 3.1. It is found that
RBE10,mix ∼ 1 at the entrance region of
1H and 4He beams. The ratio between RBE10,mix values at
the proximal (depth of ∼105mm) and distal (depth of ∼165mm) regions is larger for 16O compared
to 12C. The RBE10,mix profile for
16O demonstrates the most pronounced tail with respect to other
projectiles.
3.3 SOBP distributions of biological dose
The SOBP distributions of biological dose Dbio for
1H, 4He, 12C and 16O are shown in Figure 5. They
are calculated for HSG cell as a product of physical dose calculated with MCHIT and RBE10,mix
obtained within the MK model on the basis of microdosimetric modeling with MCHIT. All four SOBP
distributions presented in Figure 5 are 6 cm wide, and they are normalized to 1. at the plateau to
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Figure 4: RBE10,mix distributions calculated with MCHIT and the MK model for 6 cm SOBP beams
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estimated with the MK model from measured y∗ [25] are presented by full symbols as explained in the
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facilitate the comparison of their shapes and ratios between the plateau and entry channel. Therefore,
in the following the distributions of Dbio are discussed in terms of dose relative to the plateau values.
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Figure 5: SOBP biological dose profiles for 1H, 4He, 12C and 16O nuclei obtained as a product of
physical dose calculated with MCHIT and RBE10,mix shown in Figure 4. The distributions for all
projectiles were rescaled to get the same value at the plateau.
The distribution of Dbio for
12C is characterized by the lowest values at the entrance channel. This
helps to spare healthy tissues located in front of the target volume in treatments with 12C. In contrast,
the highest entrance dose is predicted for protons. However, the tail of the proton distribution beyond
the distal edge of the plateau is negligible, while it is essential both for 12C and 16O. This indicates
that the proton beam is the best option if very sensitive organs are located behind the tumor volume.
The choice of ion species for each specific treatment can, in principle, provide an optimal ratio between
the doses in the entrance and tail regions.
The distribution of Dbio for
4He demonstrates a favorably small dose at the tail region, while its
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entrance value is higher compared to 12C. The biological dose delivered by 16O to normal tissue is
slightly increased both in front of the target volume and behind it compared to 12C. From the analysis
of Dbio distributions one can conclude that
12C is the best treatment option compared to 1H, 4He and
16O, unless only a very low Dbio is acceptable in the tail region. In the latter case protons become
the best treatment option.
3.4 Distributions of cell survival fractions
The central part of our study is devoted to the comparison of survival fractions of cells Smix calculated
as a function of depth in the water phantom, which are estimated for tissues of different radiosensitivity.
This makes possible to evaluate the respective therapeutic outcome for such tissues.
The distributions of Smix calculated for cells (tissues) with (α/β)X−rays = 3.8. Gy, 2 Gy and
10 Gy after exposing them to 1H, 4He, 12C and 16O SOBP beams are shown in Figure 6. Throughout
this text the parameters for HSG cells were taken as α0 = 0.13 Gy
−1 and (α/β)X−rays = 3.8. Gy [25].
Hereafter the radiosensitivity of such tissues is considered as normal. This serves as a natural reference
point for comparison with two other tissues with their parameters taken following Kase et al. [41].
The latter two cases correspond to early responding tissue (α0 = 0.44 Gy
−1, (α/β)X−rays = 2 Gy)
very sensitive to radiation and late responding tissue (α0 = 0.04 Gy
−1, (α/β)X−rays = 10 Gy) which
is radioresistant.
The dose applied to HSG cells (normal radiosensitivity) leads to their 10% survival at the target
volume for all four beams. The beams of 4He and 12C equally well spare tissue in the entrance channel,
while the impact of 1H and 16O is stronger there. As one can expect, the main difference between
light 1H, 4He and heavier 12C, 16O is revealed beyond the distal edge of SOBP profile due to the tail
of secondary fragments from 12C and 16O. One can also note that 16O is the worst option for HSG
cells, while 4He is the best one.
In the case of early and late responding tissues, see Figure 6, middle and bottom panels, the
relation between the survival fractions estimated for 1H, 4He, 12C and 16O beyond the distal edge of
the SOBP plateau are quite similar to the case of HSG cells. This is because of the fact that the dose
in the tail region is defined by the presence of secondary fragments, which is essential for 12C and 16O
beams. In the case of early responding tissues less than 5% of cells survive in the tumor volume, but
their survival outside it is also unacceptably low (10–20%). This means that in this case there are
no advantages of charged particle therapy with respect to the intensity modulated radiation therapy
(IMRT) with photons.
In the case of late responding tissues more cells (∼ 15%) survive in the tumor volume after the
impact of 1H, 4He, 12C and 16O SOBP beams, see Figure 6, bottom panel. The 12C and 16O SOBP
beams are very effective in killing tumor cells, but the cell survival is also lower in the entrance
channel (∼ 40%) compared to ∼ 50% for 1H and 4He. By considering all three sensitivity cases one
can conclude that the 4He beam is equally suitable for irradiation of tissues with normal and low
radiosensitivity as the 12C beam. Moreover, due to the reduced fragmentation of 4He, this option can
be even better than 12C when sparing tissues after the tumor volume is crucial. At the same time the
16O beam has no clear advantages compared to 12C. Due to higher ionization in the entrance channel
and enhanced fragmentation more cells are killed by 16O beam outside the tumor volume compared to
12C beam. However, one can consider 16O is a good option for highly resistant tumors, as it effectively
kills cells in the tumor volume.
4 Conclusions
In this work we presented our approach based on Monte Carlo simulations of microdosimetric spectra
of monoenergetic beams of 1H, 4He, 12C and 16O in water. It provides y∗ values as input to the
modified MK model [36] for calculating RBE10,mix for HSG cells for SOBP distributions composed
from monoenergetic beams of these projectiles. This method gives RBE10,mix for
1H, 4He, 12C which
are in full agreement with RBE10,mix also calculated within the MK model, but from measured y
∗ [25]
and RBE10,mix calculated from the parameters of LQ fitting of survival curves of HSG cells [25]. This
makes us confident in extending our approach to 16O beams for which the respective data are not
available. Our approach provides well-adjusted biological dose distributions for 1H, 4He, 12C and 16O
with a very flat SOBP plateau. Thus basic properties of mixed radiation fields in treatments with
these projectiles are emulated.
It is found that the shapes of RBE10,mix profiles for
4He, 12C and 16O are similar to each other,
while the RBE10,mix for protons is almost constant (∼ 1.) over the whole depth in water, excluding
enhanced RBE10,mix (∼ 1.2) after the distal edge of the SOBP plateau. Considerably lower RBE10,mix
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Figure 6: Distributions of cell survival rates Smix after irradiation with
1H, 4He, 12C and 16O SOBP
beams calculated for tissues with (α/β)X−rays = 3.8. Gy (HSG cells, top panel), 2 Gy (early re-
sponding tissue, middle panel) and 10 Gy (late responding tissue, bottom panel). The values of α0
parameter of the MK model are taken as 0.13 Gy−1, 0.44 Gy−1 and 0.04 Gy−1, respectively.
values are estimated in the entrance and tail region for 4He compared to 12C and 16O. In the target
volume the highest RBE10,mix values of 1.5–2.5 are calculated for
12C and 16O.
In order to reduce side effects of ion therapy such as radionecrosis [41] the damage to surrounding
healthy tissues should be reduced as much as possible. With the help of our MCHIT model connected
with the modified MK model the severity of this damage is evaluated by calculating the cell survival
fractions in healthy tissues for several kinds of therapeutic beams (1H, 4He, 12C, 16O). We considered
the cases of normal (HSG cells), high and low radiosensitivity of tissues in the tumor volume and
around it. The consideration of the impact of 1H, 4He, 12C and 16O SOBP beams in these three cases
led us to the following conclusions:
• In the case of early responding tissues all four charged particle beams induce severe damage not
only to the target volume, but also around it. Since in this case the region of high damage is
not conformal to the target volume, the treatment with charged particles loses its advantages
with respect to treatment with photons.
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• In the case of tissues with normal radiosensitivity (HSG cells) 4He and 12C beams spare tissue
in the entrance channel better than 1H and 16O ones.
• 4He and 12C nuclei are equally suitable for irradiation of tissues with normal and low radiosen-
sitivity. The cell survival fractions calculated, respectively, for the entrance channel and target
volume are similar for 4He and 12C.
• However, as soon as it is important to spare healthy tissues after the distal edge of the SOBP
plateau, 4H can be recommended due to the reduced nuclear fragmentation of these projectiles.
• No definitive advantages of 16O with respect to 12C were found, with the except of an enhanced
impact of these heavier projectiles on radioresistant tumors.
In a recent work [42] the authors studied the possibility to spare healthy tissues by properly
selecting ion species for therapy. In addition to 1H, 4He, 12C they considered lithium, beryllium,
boron and neon ions and calculated the dose to normal tissue delivered by these beams. However,
the option of 16O was not considered, while the Heidelberger Ionenstrahl-Therapiezentrum (HIT) in
Heildeberg, Germany, provides 16O beams of therapeutic energies [43, 11] in addition to 1H, 4He, 12C.
Treatments at this facility are performed presently only with protons and carbon ions, but 16O can
be also used following respective pre-clinical studies. In this sense our study complements the results
of Remmes et al. [42] by considering 16O beams, and also by comparing cell survival profiles in 1H,
4He, 12C and 16O treatments in addition to biological dose profiles.
As suggested [44], multi modal irradiations with various nuclei can be used for LET-painting. In
this method high-LET radiation is used to boost the LET in a hypoxic sub-volume of the target
(hypoxic compartments of the tumor). At the same time low-LET radiation is applied to the comple-
mentary target volume. Such combination may increase tumor control and reduce side effects. This
means that a thorough evaluation of the physical properties and biological effectiveness of different
beams is necessary before they can be applied in real treatments. Our approach can be also used
for estimating RBE and cell survival fractions for 7Li, 8Be, 10B and 14N nuclei prior to planning
radiobiological experiments with these beams.
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